Hygea VCT plc Hygea Vct Plc : Update For The Quarter Ended 30 September 2017
November 08 2017 - 1:00AM
UK Regulatory
TIDMHYG
Hygea VCT PLC ORD 50P
Hygea VCT plc
FOR IMMEDIATE RELEASE 8 November 2017
HYGEA VCT PLC
("Hygea" or "the Company")
Update for the quarter ended 30 September 2017
Hygea vct plc presents its quarterly update for the period commencing 1
July 2017.
The Directors have recently reviewed the valuation of its portfolio as
at the quarter ended 30 September 2017.
The unaudited Net Asset Value ("NAV") per ordinary share as at 30
September 2017 was 64.0p. This is a reduction of 0.4p from the
previously published NAV for the period ended 30 June 2017, due to
running costs and a reduction in the value of Glide Pharmaceutical
Technologies Ltd: unfortunately, Glide has entered administration during
the period and its shareholders are unlikely to receive any proceeds
from the liquidation - its value has therefore been written down to
zero. No other changes have been made to the unquoted valuations.
The Company's holding in Scancell Holdings Plc ("Scancell"), listed on
AIM, represents approximately 30% of its net assets at 30 September
2017. The bid price of Scancell's shares used for the calculation of
the Company's net assets on 30 September 2017 was 12.0p, a slight
reduction from 30 June 2017. Scancell has recently announced the
appointment of a new CEO, and is continuing its preparations for
clinical trials later this year and in 2018. During the period under
review, the holding in Genedrive plc was sold for liquidity management
purposes. Omega Diagnostics plc is therefore the only other listed
holding in the portfolio, and its bid price at 30 September 2017 was
21.5p per share.
At 30 September 2017, the company had used GBP136,030 of its GBP200,000
overdraft facility, which has subsequently been renewed for a further 6
months.
In the absence of realisations, the Board continues to investigate ways
to mitigate the ongoing running costs of the Company and has had
discussions with various parties with a view to the expansion of the
capital and investment base. Once any such discussions are sufficiently
advanced, an announcement will be made but at present there is no
certainty that any of the discussions will lead to a proposal.
The Directors are not aware of any other events or transactions which
have taken place between 1 October 2017 and the publication of this
statement which have had a material effect on the financial position of
the Company.
Furthermore, in conformity with the Disclosure and Transparency Rules,
the Company notifies the market that the capital of the Company consists
of 8,115,376 Ordinary Shares with a nominal value of GBP0.50 each with
voting rights as at 7 November 2017. The Company does not hold any
Ordinary Shares in Treasury. Therefore, the total number of voting
rights in the Company is 8,115,376 (the 'Figure').
The Figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in the Company under
the FCA's Disclosure and Transparency Rules.
This announcement contains inside information for the purposes of
Article 7 of EU Regulation 596/2014.
Enquiries:
John Hustler, Hygea vct plc at john.hustler@btconnect.com
Roland Cornish, Beaumont Cornish Limited on 020 7628 3396
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Hygea VCT plc via Globenewswire
(END) Dow Jones Newswires
November 08, 2017 02:00 ET (07:00 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Seneca Growth Capital Vct (LSE:HYG)
Historical Stock Chart
From Apr 2024 to May 2024
Seneca Growth Capital Vct (LSE:HYG)
Historical Stock Chart
From May 2023 to May 2024